NVDA Q3 Earnings Alert: Why our AI stock picker is still holding Nvidia stockRead More

Indian states impose stricter lockdowns as COVID deaths hit record high

Published 05/08/2021, 12:14 AM
Updated 05/08/2021, 01:11 PM
© Reuters. Policemen stand in front of Jama Masjid or Grand Mosque on Jumat-ul-Vida or the last Friday of the holy fasting month of Ramadan, during a lockdown to limit the spread of the coronavirus disease (COVID-19), in the old quarters of Delhi, India, May 7, 2021
CSCO
-
RENA
-
GOOGL
-
AMZN
-
MBGAF
-
GOOG
-
NSANY
-

By Sudarshan Varadhan and Tanvi Mehta

CHENNAI (Reuters) -India on Saturday reported its highest ever single-day COVID-19 death toll, as cases continued to rise and states imposed stricter lockdowns.

India's health ministry reported 4,187 fatalities over the past 24 hours, taking the overall death toll close to 240,000. The Institute for Health Metrics and Evaluation estimates that India will see 1 million COVID deaths by August.

Cases rose by 401,078 on Saturday, bringing the total since the start of the pandemic to 21.9 million.

Medical experts say the real numbers of COVID-19 cases and fatalities are likely to be far higher than official tallies.

Tamil Nadu, known for its automobile manufacturing including BMW, Daimler (OTC:DDAIF), Hyundai, Ford, Nissan (OTC:NSANY) and Renault (PA:RENA), said it would move from a partial to a full lockdown on Monday, shutting public transport and state-run alcohol retailers.

Neighbouring Karnataka state extended a total shutdown late on Friday. The state capital Bengaluru is a major tech hub, home to major offices of companies including Google (NASDAQ:GOOGL), Amazon (NASDAQ:AMZN) and Cisco (NASDAQ:CSCO).

India is yet to impose a national lockdown as it did during its first wave last year, but around half of all its states have imposed a total shutdown. The rest are under a partial shutdown.

India's drug regulator on Friday approved for emergency use a new drug called 2-deoxy-D-glucose after clinical trials showed it aided the recovery of hospitalized patients and reduced dependence on supplemental oxygen.

The drug was jointly developed by India's state-run Defence Research and Development Organisation and Hyderabad-based Dr.Reddy's Laboratories Ltd .

Though it is the world's biggest vaccine maker, India is struggling to produce and distribute enough doses to stem the wave of COVID-19.

The country has administered over 167 million vaccine doses but its rate of inoculation has fallen in recent days and only around 2% of its 1.4 billion people have received the two doses needed to be fully immunised.

A CRISIS IN THE SOUTH

While cases in the country's northern and western areas have borne the brunt of the pandemic, southern states including Karnataka and Tamil Nadu have seen infections surge.

The second wave of the coronavirus pandemic in India has brought the healthcare system to the brink of collapse, with patients dying due to lack of oxygen or access to hospital beds.

Prime Minister Narendra Modi has been criticised for his handling of the oxygen shortage, though the government says it is doing all it can.

Medical journal Lancet said in an editorial on Saturday Prime Minister Modi's attempts to stifle criticism were "inexcusable."

"India must now restructure its response while the crisis rages. The success of that effort will depend on .. implementing a public health response that has science at its heart."

© Reuters. A woman mourns after her husband died due to the coronavirus disease (COVID-19) outside a mortuary of a COVID-19 hospital in Ahmedabad, India, May 8, 2021. REUTERS/Amit Dave

Tamil Nadu chief minister M.K. Stalin said in a letter to Modi late on Friday that medical oxygen demand in the state could double in the next two weeks.

"The availability of oxygen in Tamil Nadu is very very critical," Stalin said, adding that 13 patients died in a hospital on the outskirts of Chennai due to the lack of oxygen.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.